CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The Chinese pharmaceutical industry – comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines – was valued at $168.6 billion in 2010 and grew to $424.6 billion in 2016. In 2010, the pharmaceutical market for western medicine was worth $53.8 billion, which increased to $106 billion in 2016 at a CAGR of 12%. It is forecast to be $132.9 billion in 2018 and reach $209 billion by 2022. The Chinese medical device market was valued at $36 billion in 2015, which increased to $40.1 billion in 2017. Since 2015, the China Food and Drug Administration (CFDA) has released several policies to reform the pharmaceutical market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China
  • Porter’s five forces analysis for pharmaceutical and medical devices market of China
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Chinese healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market

Table of Contents

1 Table of Contents

1.1 List of Figures

1.2 List of Tables

2 Executive Summary

2.1 Executive Summary – Overview

2.2 Key ...

1 Table of Contents

1.1 List of Figures

1.2 List of Tables

2 Executive Summary

2.1 Executive Summary – Overview

2.2 Key Highlights

2.3 Key Events: Chinese Pharmaceutical History, 2007–2018

2.4 Key Events: Chinese Pharmaceutical Market

2.5 Key Events: M&A, VF & PE Deals, Global Pharmaceutical Market, 2017–2018

2.6 Key Events: Mergers and Acquisitions

2.7 Country Profile, China, 2017

3 Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – US–China Trade War

3.5 Pharmaceutical Market – Supply Channels

3.6 Pharmaceutical Market – Market Segments

3.7 Pharmaceutical Market – Top Five Disease Areas

3.8 Pharmaceutical Market – Major Players

4 Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Device Market – Top Five Segments

4.3 Medical Device Market – Diagnostic Market

4.4 Medical Device Market – Major Players

5 Pharmaceutical and Medical Device Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6 Deal analysis

6.1 Deal Analysis: M&A, VF and PE Deals, Pharmaceutical Market, China

6.2 Deal Analysis: M&A, VF and PE Deals, Medical Device Market, China

7 Pharmaceutical and Medical Device Market – Porter’s Five Forces Analysis

7.1 Pharmaceutical Market, China – Porter’s Five Forces Analysis

7.2 Medical Device Market, China – Porter’s Five Forces Analysis

8 Market Access

8.1 Overview of Healthcare System, China

8.2 Reimbursement Process, China

8.2.1 Overview of Public & Private Insurance, China

8.2.2 Healthcare Spending and Price Trends in the Healthcare Sector, China

8.2.3 Pricing Policies, China

8.3 Regulatory Landscape, China

8.3.1 CFDA Reforms 2015–2017, China

8.3.2 Market Authorization for Pharmaceutical Drugs, China

8.3.3 Market Authorization for Generic Drugs, China

8.3.4 Market Authorization for Medical Devices, China

8.3.5 Intellectual Property Rights, Patent, China

8.3.6 Intellectual Property Rights, Patent Linkage System, China

8.3.7 Intellectual Property Rights, Trademark, China

8.3.8 Pharmaceutical Advertising Regulations, China

8.3.9 Labeling and Packaging Regulations, China

9 Country Healthcare Landscape

9.1 Healthcare Policy Highlights

9.2 Healthcare Facilities

9.3 Healthcare Parameters

9.4 Environmental Health

9.5 Healthcare Personnel

9.6 Disease Burden

9.7 Healthcare Expenditure

9.7.1 Healthcare Expenditure – Overview

9.7.2 Share of Public and Private Sectors

10 Trade Associations

11 Trade Fairs, China

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.1.4 Expert Panel

13.2 Bibliography

13.3 Contact Us

13.4 Disclaimer

List of Tables

Table 1: Biosimilars in Development by Chinese Companies, China, 2016

Table 2: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016 ...

Table 1: Biosimilars in Development by Chinese Companies, China, 2016

Table 2: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016

Table 3: Ophthalmic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015

Table 4: Orthopedic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017

Table 5: Diagnostic Imaging Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015

Table 6: Nephrology and Urology Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2016

Table 7: Cardiovascular Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017

Table 8: Drug Classification System, China, 2017

Table 9: Medical Device Classification, China, 2016

Table 10: Trademark Process Timeline, China, 2017

Table 11: Documents for Advertising Application, China, 2017

Table 12: Label/Insert Sheet Information, China, 2017

Table 13: Key Improvement Indicators, Healthy China 2030

Table 14: Trade Fairs, China, 2018–2019

List of Figures

Figure 1: Pharmaceutical Market, China, Revenue ($bn), 2010–2017

Figure 2: Medical Device Market, China, Revenue ($bn), 2015–2020

Figure 3: Country Profile, China, 2017 ...

Figure 1: Pharmaceutical Market, China, Revenue ($bn), 2010–2017

Figure 2: Medical Device Market, China, Revenue ($bn), 2015–2020

Figure 3: Country Profile, China, 2017

Figure 4: Pharmaceutical Market, China, Revenue ($bn), 2010–2017

Figure 5: Pharmaceutical Market, China, Revenue Forecast ($bn), 2018–2022

Figure 6: Pharmaceutical Exports ($bn), China, 2010–2017

Figure 7: Top Export Partners, China, 2017

Figure 8: Pharmaceutical Imports ($bn), China, 2010–2017

Figure 9: Top Import Partners, China, 2017

Figure 10: USTR Findings, 2018

Figure 11: US-China Trade War Timeline, 2018

Figure 12: Pharmaceutical Drug Sales Channel, China, 2016

Figure 13: Supply Chain Prior to 2017

Figure 14: Two Invoice System

Figure 15: Policies for Biosimilar Promotion, China, 2018

Figure 16: Major Biosimilar Sales ($m), China, 2016

Figure 17: Traditional Chinese Medicine Production (10,000 tons), China, 2010–2016

Figure 18: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016

Figure 19: Pharmaceutical Market, Major Players, 2017

Figure 20: Medical Device Market, China, Revenue ($bn), 2015–2020

Figure 21: Medical Device Market, China, Revenue Forecast ($bn), 2021–2025

Figure 22: Medical Device Market, China, Revenue by Segment ($bn), 2017

Figure 23: Ophthalmic Devices Market, China, Revenue ($m), 2015–2022

Figure 24: Ophthalmic Devices Market, China, Market Share of Major Players (%), 2015

Figure 25: Orthopedic Devices Market, China, Revenue ($m), 2015–2020

Figure 26: Orthopedic Devices Market, China, Market Share of Major Companies (%), 2017

Figure 27: Diagnostic Imaging Devices Market, China, Revenue ($bn), 2015–2020

Figure 28: Diagnostic Imaging Devices Market, China, Market Share of Major Players (%), 2015

Figure 29: Nephrology and Urology Devices Market, China, Revenue ($m), 2015–2022

Figure 30: Nephrology and Urology Devices Market, China, Market Share of Major Players (%), 2016

Figure 31: Cardiovascular Devices Market, China, Revenue ($bn), 2015–2022

Figure 32: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2017

Figure 33: Diagnostic Market, China, Revenue ($bn), 2015–2020

Figure 34: Diagnostic Market, China, Revenue ($bn), 2021–2025

Figure 35: Medical Device Market, China, Revenue ($bn) of Major Companies, 2017

Figure 36: Deal Value and Deal Count, Pharmaceutical Market, China, 2017–2018

Figure 37: Deal Value and Deal Count Quarterly, Pharmaceutical Market, China, 2017–2018

Figure 38: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2017–2018

Figure 39: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, China, 2017–2018

Figure 40: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2017–2018

Figure 41: M&A Deals by Therapy Area, Pharmaceutical Market, China, 2017–2018 (by value and count)

Figure 42: Venture Financing Deals by Therapy Area, Pharmaceutical Market, China, 2017–2018 (by value and count)

Figure 43: Private Equity Deals by Therapy Area, Pharmaceutical Market, China, 2017–2018 (by value and count)

Figure 44: Medical Device Market Deals (by deal value, $bn), China, 2017–2018

Figure 45: Medical Device Market Deals (by deal count), China, 2017–2018

Figure 46: Medical Device Market Deals Share (by deal count), China, 2017–2018

Figure 47:Medical Device Market Deals Share (by deal value), China, 2017–2018

Figure 48: Medical Device, China, Top Therapy Area by Deal Value, 2017–2018

Figure 49: Medical Devices, China, M&A Deals by Therapy Area, 2017–2018

Figure 50: Medical Devices, China, Venture Financing Deals by Therapy Area, 2017–2018

Figure 51: Medical Devices, China, Top Therapy Area by Deal Number, 2017–2018

Figure 52: Medical Devices, China, Private Equity Deals by Therapy Area, 2017–2018

Figure 53: Healthcare System, China, 2017

Figure 54: National Reimbursement Drug List Process, China, 2017

Figure 55: National Reimbursement Drug List Classification, China, 2017

Figure 56: Public Insurance Schemes, China, 2017

Figure 57: Out-of-Pocket Expenditure (% of total expenditure on health), China, 2010–2017

Figure 58: Annual Rate of Change (%), Health Care Price Index, China, 2010–2016

Figure 59: Pricing Policies, China, 2017

Figure 60: Drug Movement from Market Authorization to Patient Use, China, 2016

Figure 61: Ministry of Food and Drug Safety, Organization Chart, 2017

Figure 62: Timeline of CFDA Reforms, China, 2015–2018

Figure 63: Center for Drug Evaluation Organization Chart, China, 2017

Figure 64: Drug Approval Process, China, 2017

Figure 65: Generic Drug Approval Process, China, 2017

Figure 66: Medical Device Approval Process, China, 2017

Figure 67: Patent Approval Process, China, 2016

Figure 68: Proposed Patent Linkage System, China, 2017

Figure 69: Trademark Process, China, 2017

Figure 70: Advertising Application Approval Process, China, 2017

Figure 71: Key Announcements and Updates, Healthy China 2020, 2009–2016

Figure 72: Healthy China 2030, Strategic Goals

Figure 73: Hospitals (Number), China, 2010–2017

Figure 74: Hospitals by Type (Number), China, 2010–2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

Syndicated reports are detailed with easy referencing, and even the forecast models are detailed with analyst references along with most comprehensive M&A database

  Adamas Pharmaceuticals, Inc.